1197-21-3

Usage

Uses

Used in Pharmaceutical Industry:
Phentermine Hydrochloride is used as a controlled substance for its stimulant properties, specifically to treat obesity. It functions as an anorexic agent, helping to reduce appetite and promote weight loss in individuals struggling with obesity. The drug is also used in combination with diet and exercise to manage weight in patients with certain health conditions.
Additionally, Phentermine Hydrochloride is used as an appetite suppressant in the weight management industry, where it is prescribed to individuals who require short-term assistance in controlling their food intake.

Therapeutic Function

Antiobesity

InChI:InChI=1/C10H15N.ClH/c1-10(2,11)8-9-6-4-3-5-7-9;/h3-7H,8,11H2,1-2H3;1H

Upstream product

• 5531-33-9 N-(2-methyl-1-phenylpropan-2-yl)acetamide 
• 83386-09-8 2-azido-2-methyl-3-phenylpropane 
• 5669-14-7 2,2-dimethyl-3-phenylpropanoic acid 
• 53478-07-2 3-benzyloxy-5-carboxyphenylglyoxal 
• 122-09-8 Phentermin 
• 6921-34-2 benzylmagnesium chloride 
• 100-86-7 2-Methyl-1-phenyl-2-propanol 
• 1754-74-1 2-chloro-2-methyl-1-phenylpropane 
• 100-39-0 benzyl bromide 
• 97847-79-5 C₂₂H₂₄NOP 

Downstream Products

• 61765-66-0 N-(2-methyl-1-phenylpropan-2-yl)-1-phenylmethanimine 
• 82408-64-8 N-(1,1-dimethyl-2-(4-nitrophenyl)ethyl)amine 
• 881206-52-6 N₄-methyl-N₂-(2-methyl-1-phenylpropan-2-yl)-N₄-(2-phenylpyrimidin-4-yl)pyrimidine-2,4-diamine 
• 1227910-89-5 6-chloro-N₄-(1,1-dimethyl-2-phenylethyl)-2,4-pyrimidinediamine 
• 42524-63-0 N-(1,1-dimethyl-2-phenylethyl)-2,2,2-trifluoroacetamide 
• 26307-22-2 N,N'-bis(2-methyl-3-phenyl-2-propyl)diazene 
• 128232-11-1 5-<2-<<1-(4-iodophenyl)-2-methylprop-2-yl>amino>-1-hydroxyethyl>-8-hydroxycarbostyril 
• 128232-09-7 8-Benzyloxy-5-{1-hydroxy-2-[2-(4-iodo-phenyl)-1,1-dimethyl-ethylamino]-ethyl}-1H-quinolin-2-one 
• 96684-29-6 2-amino-2-methyl-1-(4-iodophenyl)propane 
• 51131-55-6 4-(β-amino-isobutyl)-aniline 
• 200631-40-9 3,3-dimethyl-2-tosyl-1,2,3,4-tetrahydroisoquinoline 
• 28459-83-8 3,3-dimethyl-1,2,3,4-tetrahydroisoquinoline 
• 28460-55-1 3,3-dimethyl-3,4-dihydroisoquinoline 
• 731749-75-0 (1,1-dimethyl-2-phenyl-ethyl)-(4-methoxy-benzyl)-amine 

Relevant academic research and scientific papers

CHEMICAL COMPOUNDS

The invention is directed to 6-(4-pyι?midinyl)-1 H-indazole derivatives. Specifically, the invention is directed to compounds according to Formula (I) wherein R1 - R4 are defined herein. The compounds of the invention are inhibitors of PDK1 and can be useful in the treatment of immune and metabolic diseases and disorders characterized by constitutively activated ACG kinases such as cancer and more specifically cancers of the breast, colon, and lung. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PDK1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

CHEMICAL COMPOUNDS

The invention is directed to to substituted indazole derivatives. Specifically, the invention is directed to compounds according to Formula I: wherein R1 - R6 and X are defined herein. The compounds of the invention are inhibitors of PDK1 and can be useful in the treatment of disorders characterized by constitutively activated ACG kinases such as cancer and more specifically leukemia and cancers of the breast, colon, and lung. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PDK1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE

The present invention relates to pyridines, pyrimidines and derivatives thereof, and pharmaceutically acceptable salts thereof. Also included is a method of treatment of inflammation, rheumatoid arthritis, Pagets disease, osteoporosis, multiple myeloma, uveititis, acute or chronic myelogenous leukemia, pancreatic beta cell destruction, osteoarthritis, rheumatoid spondylitis, gouty arthritis, inflammatory bowel disease, adult respiratory distress syndrome (ARDS), psoriasis, Crohn's disease, allergic rhinitis, ulcerative colitis, anaphylaxis, contact dermatitis, asthma, muscle degeneration, cachexia, Reiter's syndrome, type I diabetes, type II diabetes, bone resorption diseases, graft vs. host reaction, Alzheimer's disease, stroke, myocardial infarction, ischemia reperfusion injury, atherosclerosis, brain trauma, multiple sclerosis, cerebral malaria, sepsis, septic shock, toxic shock syndrome, fever, myalgias due to HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses or herpes zoster infection in a mammal comprising administering an effective amount a compound as described above.

A Simple, One-Pot Transformation of t-Alkyl Chlorides Into (t-Alkyl)amines

t-Alkyl chlorides are readily azidated using trimethylsilyl azide in the presence of tin tetrachloride.Tertiary azides can be transformed without isolation into the corresponding (t-alkyl)amine hydrochlorides in a one-pot procedure employing the Staudinger reaction.

Azo Anions in Synthesis: α-Amino Carbanion Equivalents from t-Butyldiphenylmethylhydrazones

α-Amino carbanion equivalents (=C(1-)NH2) and α-hydrazino anion equivalents (=C(1-)NHNH2) are readily accessible from the C-alkylation products of t-butyldiphenylmethylhydrazones; these azoalkanes can be efficiently transformed into amines, hydrazines, and also alkanes under mild reaction conditions.

1-DIPHENYLPHOSPHINYL-2,2-DIMETHYLAZIRIDINE - A NEW PRECURSOR OF α,α-DIMETHYLARYLALKYLAMINES

The new synthesis of α,α-dimethylarylalkylamines from 1-diphenylphosphinyl-2,2-dimethylaziridine is described.

RADICAL STABILIZING EFFECTS. A COMPARISON OF TRANSITION STATE EFFECTS (RATES OF AZOALKANE DECOMPOSITIONS) WITH CALCULATED (AB INITIO) PI SPIN DENSITIES

Rate studies on five azoalkanes (4a-e) have been studied to assess important radical stabilizing effects.MO calculations of spin densities for three radicals with pi systems are correlated with kinetic rates of radical formation.

5-Hydroxy-α-(substituted aminomethyl)-m-xylene-α,α'-diols

Compounds of the formula: STR1 are disclosed, wherein R1 and R2 are hydrogen; or where R1 is methyl, R2 is hydrogen, phenyl, or phenyl substituted in the para-position by hydroxy, alkoxy, chloro, phenyl or alkyl having 1-6 carbon atoms. The compounds of this invention are useful in the treatment of bronchial asthma. These compounds exhibit unique biological properties in that they provide the desired bronchial dilation effect without accompanying cardiac stimulation.